Faron Pharmaceuticals has presented positive Phase 1 data from its BEXMAB study at the 65th American Society of Hematology (ASH) Annual Meeting. The study is evaluating the safety and efficacy of bexmarilimab, a novel anti-Clever-1 humanized antibody, in patients with aggressive myeloid leukemias. The data showed a significant overall response rate (ORR) in both higher-risk myelodysplastic syndrome (MDS) patients and MDS patients who had failed previous treatment with hypomethylating agents. The responses were deep and durable, with a majority of MDS patients achieving complete or partial remission. The combination of bexmarilimab and azacitidine was well-tolerated, and immune-related adverse events were observed at higher dose levels. The study also confirmed target engagement and immune response activation in treated patients. The positive results support the advancement of the BEXMAB study to Phase 2 and further regulatory interactions for a Biologics License Application (BLA) filing.